Literature DB >> 16359346

CYP2C19 genotype and the PPIs--focus on rabeprazole.

P W Y Lim1, K L Goh, B C Y Wong.   

Abstract

Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16359346     DOI： 10.1111/j.1440-1746.2005.04167.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN： 0815-9319            Impact factor:   4.029


  12 in total

Review 1.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 2.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

3.  Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial.

Authors:  Victoria P Y Tan; Wai M Wong; Ting K Cheung; Kam C Lai; Ivan F N Hung; Pierre Chan; Roberta Pang; Benjamin C Y Wong
Journal:  J Gastroenterol       Date:  2011-05-03       Impact factor: 7.527

Review 4.  Proton pump inhibitors: do differences in pharmacokinetics translate into differences in clinical outcomes?

Authors:  Kwong Ming Fock; Tiing Leong Ang; Lean Choo Bee; Edmund Jon Deon Lee
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 5.  Treatment of Helicobacter pylori infection: Current and future insights.

Authors:  Maliheh Safavi; Reyhaneh Sabourian; Alireza Foroumadi
Journal:  World J Clin Cases       Date:  2016-01-16       Impact factor: 1.337

6.  Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population.

Authors:  Hsiang-Yao Shih; Sophie S W Wang; Chao-Hung Kuo; Fu-Chen Kuo; Yi-Yu Chen; Meng-Chieh Wu; Bi-Chuang Weng; Yi-Chern Lee; Chi-Tan Hu; Deng-Chyang Wu; Yen-Hsu Chen
Journal:  Gastroenterol Res Pract       Date:  2012-07-04       Impact factor: 2.260

7.  Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.

Authors:  Jian-Jun Zou; Shao-Liang Chen; Jie Tan; Ling Lin; Ying-Ying Zhao; Hai-Mei Xu; Song Lin; Juan Zhang; Hong-Wei Fan; Hong-Guang Xie
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

8.  Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea.

Authors:  Yoon Jin Choi; Nayoung Kim; In-Jin Jang; Joo-Youn Cho; Ryoung Hee Nam; Ji Hyun Park; Hyun Jin Jo; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyun Chae Jung
Journal:  Gut Liver       Date:  2017-07-15       Impact factor: 4.519

9.  Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials.

Authors:  Hui-Lin Tang; Yan Li; Yong-Fang Hu; Hong-Guang Xie; Suo-Di Zhai
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

10.  A real world report on intravenous high-dose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding.

Authors:  Lung-Sheng Lu; Sheng-Chieh Lin; Chung-Mou Kuo; Wei-Chen Tai; Po-Lin Tseng; Kuo-Chin Chang; Chung-Huang Kuo; Seng-Kee Chuah
Journal:  Gastroenterol Res Pract       Date:  2012-07-11       Impact factor: 2.260
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.